Natco Pharma Ltd

Natco Pharma today updates on the legal proceedings on Risdiplam launch in India. The Company has received numerous enquiries from investors and patients about the launch, availability and pricing of generic version of Risdiplam in the Indian market. The Company wishes to clarify that the Ld. Single Judge of Delhi High Court had through order dated 24 March 2025 denied Roche's plea for an injunction against the Company for the drug. However, Roche has appealed the decision before the Appellate Bench of the Delhi High Court who has currently directed to maintain the status quo. Due to pendency of the proceedings before the court, the Company does not wish to comment on the status of the proceedings. However, it has been the stand of the Company that it intends to launch the drug only after and subject to successful clarity from the Appellate Bench of the Delhi High Court which is expected shortly. Subject to the foregoing, the Company has decided to price the product at Rs 15,900 MRP consistent with the Company's stand before the court. The Company also intends to offer discount to certain deserving patients through its patient access programme.Powered by Capital Market - Live

Natco Pharma Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 823.5, up 0.06% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.14% on the day, quoting at 22577. The Sensex is at 74336.54, down 0%. Natco Pharma Ltd has dropped around 35.76% in last one month. Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has dropped around 5.72% in last one month and is currently quoting at 20423.35, up 0.02% on the day. The volume in the stock stood at 3.53 lakh shares today, compared to the daily average of 19.39 lakh shares in last one month.The PE of the stock is 8.31 based on TTM earnings ending December 24.Powered by Capital Market - Live

Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 837, up 1.69% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.08% on the day, quoting at 22571.15. The Sensex is at 74623.15, up 0.23%. Natco Pharma Ltd has dropped around 28.81% in last one month. Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has dropped around 4.72% in last one month and is currently quoting at 20389.7, down 0.5% on the day. The volume in the stock stood at 6.37 lakh shares today, compared to the daily average of 15.09 lakh shares in last one month.The PE of the stock is 8.31 based on TTM earnings ending December 24.Powered by Capital Market - Live

Orchid Pharma Ltd, Vijaya Diagnostic Centre Ltd, FDC Ltd and Aegis Logistics Ltd are among the other losers in the BSE's 'A' group today, 13 February 2025.Natco Pharma Ltd lost 20.00% to Rs 973.35 at 14:48 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 3.29 lakh shares were traded on the counter so far as against the average daily volumes of 33889 shares in the past one month.Orchid Pharma Ltd crashed 15.85% to Rs 1038.75. The stock was the second biggest loser in 'A' group.On the BSE, 62126 shares were traded on the counter so far as against the average daily volumes of 13126 shares in the past one month.Vijaya Diagnostic Centre Ltd tumbled 7.73% to Rs 947. The stock was the third biggest loser in 'A' group.On the BSE, 1.12 lakh shares were traded on the counter so far as against the average daily volumes of 30189 shares in the past one month.FDC Ltd pared 6.59% to Rs 411.05. The stock was the fourth biggest loser in 'A' group.On the BSE, 41640 shares were traded on the counter so far as against the average daily volumes of 4004 shares in the past one month.Aegis Logistics Ltd shed 6.44% to Rs 743.5. The stock was the fifth biggest loser in 'A' group.On the BSE, 1.24 lakh shares were traded on the counter so far as against the average daily volumes of 1.12 lakh shares in the past one month.Powered by Capital Market - Live

Natco Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 997, down 18.2% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.53% on the day, quoting at 23166.7. The Sensex is at 76563.26, up 0.51%.Natco Pharma Ltd has eased around 20.67% in last one month.Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has eased around 2.85% in last one month and is currently quoting at 21142.05, up 2.03% on the day. The volume in the stock stood at 68.97 lakh shares today, compared to the daily average of 4.46 lakh shares in last one month.The PE of the stock is 11.85 based on TTM earnings ending September 24.Powered by Capital Market - Live

Profit before tax in Q3 FY25 stood at Rs 163.7 crore, down 36.13% as against Rs 256.3 crore reported in the same period a year ago. The company's revenue from active pharmaceutical ingredient (API) stood at Rs 66.6 crore (up 43.84% YoY), income from domestic formulations was at Rs 96.1 crore (down 3.32% YoY), and revenue from crop health sciences (CHS) came in at Rs 15.1 crore (up 7.09% YoY) during the period under review. On the other hand, revenue from export formulations slipped 52.81% YoY to Rs 285.8 crore during the quarter. Meanwhile, the company's board declared a second interim dividend of Rs 1.50 per equity share in FY25. The record date for the same is fixed on 18 February 2025. The payment of the dividend will start on 28 February 2025. Further, the company informed us that Dr. Pavan Ganapati Bhat, director & executive vice president (technical operations) of the company, has tendered his resignation due to a new career opportunity outside the company. Natco Pharma is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing, and selling of bulk drugs and finished dosage formulations. The company has manufacturing facilities in India, which cater to both domestic and international markets, including regulated markets like the United States of America and Europe.Powered by Capital Market - Live

Net profit of Natco Pharma declined 37.47% to Rs 133.00 crore in the quarter ended December 2024 as against Rs 212.70 crore during the previous quarter ended December 2023. Sales declined 37.41% to Rs 474.80 crore in the quarter ended December 2024 as against Rs 758.60 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales474.80758.60 -37 OPM %8.1735.34 - PBDT210.70300.50 -30 PBT163.70256.30 -36 NP133.00212.70 -37 Powered by Capital Market - Live

Natco Pharma announced that the Board of Directors of the Company at its meeting held on 12 February 2025, has recommended a Third Interim dividend of Rs.1.50 per share (i.e.75%), subject to the approval of the shareholders.Powered by Capital Market - Live

The company's marketing partner for the ANDA, Lupin Pharmaceuticals Inc. (Lupin), will market the product in the U.S. NATCO believes it has sole first-to-file status for the product and is eligible for a 180-day exclusivity at the time of launch. Bosentan TFOS is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability. Bosentan tablets for oral suspension (TFOS) had estimated sales of $11 million in the U.S. for 12 months ending September 2024, as per industry sales data. Natco Pharma is engaged in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The company has manufacturing facilities in India, which cater to both domestic and international markets, including regulated markets like the United States of America and Europe. The company's consolidated net profit surged 83.55% to Rs 677.30 crore on a 32.93% increase in revenue from operations to Rs 1,371.1 crore in Q2 FY25 over Q2 FY24. The scrip fell 1.24% to currently trade at Rs 1302.35 on the BSE. Powered by Capital Market - Live

Natco Pharma announced final approval of its ANDA for Bosentan tablets for oral suspension (TFOS), 32mg, a generic version of Tracleer' by Actelion Pharmaceuticals US Inc. NATCO's marketing partner for the ANDA, Lupin Pharmaceuticals, Inc. (Lupin) will market the product in the U.S. Natco Pharma believes it has sole First-to-File status for the product and is eligible for a 180-day exclusivity at the time of launch. Launch details are bound by confidentiality. Bosentan TFOS is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability. Bosentan tablets for oral suspension (TFOS), 32mg had estimated sales of USD 11 million in the U.S. for 12 months ending Sep'24 as per industry sales data.Powered by Capital Market - Live